Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET).

Giuseppe LambertiNatalie PrinziAlberto Bongiovanni Mariangela TorniaiElisa AndriniDario de Biase Deborah MalviMirta MoscaRossana BerardiToni IbrahimSara PuscedduDavide Campana

Published in: Diagnostics (Basel, Switzerland) (2023)

FOLFOX/XELOX chemotherapy is active as the first-line treatment of patients with G3 GEP-NET. The mutational landscape of G3 NET is more similar to well-differentiated NETs than NECs.

Keyphrases

neuroendocrine tumors
locally advanced
single cell
cancer therapy
type diabetes
squamous cell carcinoma
metabolic syndrome
copy number
chemotherapy induced
adipose tissue
drug delivery